FDA Broadens Access to Over-the-Counter Naloxone Nasal Spray for Opioid Overdose
press_releaseUnited States·U.S. Food and Drug Administration·Wire Summary
The U.S. Food and Drug Administration (FDA) today approved another over-the-counter (OTC) intranasal naloxone product, Rextovy, a 4 milligram (mg) naloxone hydrochloride nasal spray for the emergency treatment of opioid overdose.
AI Business Impact
How does this affect your business?
Get an AI analysis of this article grounded in your jurisdictions, practice areas, and any policy documents you've uploaded to Wansom.